PersonExecutiveInvestor
Alexander Casdin
Alexander Casdin is the Chief Executive Officer of Epirium Bio, a San Diego biotechnology company developing small-molecule therapies to improve muscle function. A healthcare executive and institutional investor with more than 25 years in the industry, he stepped up from CFO and COO to CEO on January 1, 2025, the same month Epirium's lead drug MF-300 - a first-in-class oral 15-PGDH inhibitor for sarcopenia - cleared the FDA to begin human trials. Before Epirium he founded and ran Reneo Capital Management, was CFO of Sophiris Bio, and ran VP of Finance at Amylin Pharmaceuticals, and he sits on the board of Erasca as audit committee chair.
alexander casdinalex casdinepirium bioceobiotechhealthcare investor
